CELCUITY INC

Company Overview

Celcuity is a clinical‑stage biotechnology company developing gedatolisib, an IV small molecule that inhibits Class I PI3K isoforms and both mTOR complexes, primarily targeted at HR+/HER2‑ advanced/metastatic breast cancer and mCRPC. Key development programs include the Phase 3 VIKTORIA‑1 (separate PIK3CA WT and MT cohorts — WT topline reported Q2 2025 with MT ongoing), planned VIKTORIA‑2 (initiation expected Q2 2025) and a Phase 1b/2 prostate study; the company has deprioritized its CELsignia diagnostic to concentrate resources on gedatolisib. Celcuity in‑licenses gedatolisib from Pfizer, outsources manufacturing to CMOs, remains pre‑revenue, and has been ramping R&D spend (net losses and operating cash use increased materially in 2024–H1 2025) while managing milestone/royalty obligations and financing covenants.

Executive Compensation Practices

As a pre‑revenue biotech, Celcuity’s executive pay is likely dominated by equity‑linked incentives (stock options, RSUs and performance‑vested awards) tied to clinical, regulatory and commercialization milestones (e.g., VIKTORIA topline, NDA filing and approval), with relatively modest cash salaries and discretionary bonuses. The company explicitly calls out stock‑based compensation valuation as a critical accounting policy, so grant size, strike prices and performance conditions materially affect reported results and executive wealth. Recent capital raises (equity offerings, convertible notes, loan tranches with attached warrants) and the need to retain talent for accelerated pivotal programs increase the probability of retention grants, milestone bonuses and potential change‑of‑control protections as part of compensation design.

Insider Trading Considerations

Insider trading at Celcuity will likely cluster around discrete development and financing catalysts — trial readouts (VIKTORIA cohorts), NDA milestones, patent grants and announced financings — so Form 4 activity should be checked closely around those dates. Expect common practices such as 10b5‑1 trading plans and blackout periods prior to material clinical or regulatory announcements; post‑financing lock‑ups or contractual restrictions tied to the A&R loan, convertible notes or underwriting agreements may also limit insider sales. Given frequent capital raises and meaningful dilution risk (warrants, conversions, milestone payments to Pfizer), insider sales may reflect liquidity needs rather than negative information, while open‑market purchases or option exercises ahead of positive readouts can be a higher‑conviction bullish signal.